SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-62.11	-41.45	-27.06
Net Income Net Income Growth	-56.05	-39.87	-29.16
Earnings Per Share EPS Growth	-3.88	-17.98	-16.31
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	234.19	107.44	16.27
Total Debt Total Debt Growth	1.63	1.58	3.9
Net Cash (Debt) Net Cash Growth	232.55	105.85	12.37
Net Cash Growth	1779.83%	755.66%	-
Net Cash Per Share Net Cash Per Share Growth	16.09	47.74	6.92

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-46.56	-32.7	-22.03
Capital Expenditures CapEx Growth	-3.18	-0.79	-1.99
Free Cash Flow Free Cash Flow Growth	-49.74	-33.49	-24.02
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 14, 2026

Data Sources Report a data error